Skip to content

Clinical trials

Phase 3 Neurocognitive Disorders trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Neurocognitive Disorders Phase: Phase 3 Clear all

8 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20161
20171
20181
20211
20221
20231
20241
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Terminated4
Active, not recruiting2
Completed1
Recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Eli Lilly and Company2
Negovsky Reanimatology Research Institute2
Alzheon Inc.1
AstraZeneca1
Hoffmann-La Roche1
University of Pennsylvania1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Neurocognitive Disorders8
Alzheimer Disease6
Dementia6
Central Nervous System Diseases5
Mental Disorders5
Nervous System Diseases5
Neurodegenerative Diseases5
Brain Diseases4
Tauopathies4
Carotid Artery Diseases2

Trials

Showing 26 to 8 of 8. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.